{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:42:38Z","timestamp":1790037758392,"version":"4.0.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005930","name":"ASCRS Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570156"],"award-info":[{"award-number":["81570156"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770126"],"award-info":[{"award-number":["81770126"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770161"],"award-info":[{"award-number":["81770161"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program key projects","doi-asserted-by":"publisher","award":["201607010072"],"award-info":[{"award-number":["201607010072"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ejphar.2018.11.012","type":"journal-article","created":{"date-parts":[[2018,11,10]],"date-time":"2018-11-10T11:29:54Z","timestamp":1541849394000},"page":"145-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway"],"prefix":"10.1016","volume":"843","author":[{"given":"Yan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manman","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xutao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siting","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2018.11.012_bib1","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1182\/blood.V89.6.2067","article-title":"Mantle cell lymphoma: a clinicopathologic study of 80 cases","volume":"89","author":"Argatoff","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2018.11.012_bib2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/ncponc0905","article-title":"Mechanisms of disease: angiogenesis and the management of breast cancer","volume":"4","author":"Banerjee","year":"2007","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.ejphar.2018.11.012_bib3","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1182\/blood-2015-01-624585","article-title":"Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma","volume":"126","author":"Bhatt","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2018.11.012_bib4","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1158\/1535-7163.MCT-06-0193","article-title":"Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis","volume":"5","author":"Blum","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejphar.2018.11.012_bib5","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3109\/10428194.2011.555892","article-title":"Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group","volume":"52","author":"Buckstein","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejphar.2018.11.012_bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00001622-200109000-00003","article-title":"Diffuse large cell lymphoma","volume":"13","author":"Coiffier","year":"2001","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.ejphar.2018.11.012_bib7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc2403","article-title":"VEGF-targeted therapy: mechanisms of anti-tumour activity","volume":"8","author":"Ellis","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejphar.2018.11.012_bib8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ejphar.2018.11.012_bib9","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2032Etude des Lymphomes de l\u2032Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2018.11.012_bib10","first-page":"123","article-title":"Clinical advances in the development of novel VEGFR2 inhibitors","volume":"2","author":"Fontanella","year":"2014","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ejphar.2018.11.012_bib11","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.2353\/ajpath.2007.060901","article-title":"Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes","volume":"170","author":"Gratzinger","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2018.11.012_bib12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/labinvest.3700697","article-title":"Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy","volume":"88","author":"Gratzinger","year":"2008","journal-title":"Lab Investig."},{"key":"10.1016\/j.ejphar.2018.11.012_bib13","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.cellsig.2007.05.013","article-title":"Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition","volume":"19","author":"Holmes","year":"2007","journal-title":"Cell Signal"},{"key":"10.1016\/j.ejphar.2018.11.012_bib14","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1186\/1471-2407-14-820","article-title":"Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer","volume":"14","author":"Hu","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejphar.2018.11.012_bib15","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1182\/blood-2014-06-538504","article-title":"I treat Burkitt lymphoma in adult","volume":"124","author":"Jacobson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2018.11.012_bib16","first-page":"1641","article-title":"Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection","volume":"336","author":"Kaplan","year":"1997","journal-title":"Natl. Inst. Allergy Infect. Dis. AIDS Clin. Trials Group. N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.11.012_bib17","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ejca.2010.12.016","article-title":"Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas","volume":"47","author":"Kummar","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejphar.2018.11.012_bib18","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ctrv.2012.05.003","article-title":"Targeted agents in the third-\/fourth-line treatment of patients with advanced (stage III\/IV) non-small cell lung cancer (NSCLC)","volume":"39","author":"Langer","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ejphar.2018.11.012_bib19","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2013.48.8585","article-title":"Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial","volume":"31","author":"Li","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2018.11.012_bib20","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1186\/1471-2407-10-529","article-title":"Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies","volume":"10","author":"Li","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejphar.2018.11.012_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00280-006-0403-6","article-title":"Challenges for patient selection with VEGF inhibitors","volume":"60","author":"Longo","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.11.012_bib22","doi-asserted-by":"crossref","first-page":"38892","DOI":"10.18632\/oncotarget.6476","article-title":"RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action","volume":"7","author":"Masliah-Planchon","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2018.11.012_bib23","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1634\/theoncologist.2008-0261","article-title":"Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions","volume":"14","author":"Morabito","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.ejphar.2018.11.012_bib24","doi-asserted-by":"crossref","first-page":"17220","DOI":"10.18632\/oncotarget.7948","article-title":"Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma","volume":"7","author":"Peng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2018.11.012_bib25","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00280-011-1589-9","article-title":"Aflibercept-mediated early angiogenic changes in aggressive B-cell lymphoma","volume":"68","author":"Romero","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.11.012_bib26","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V96.12.3712","article-title":"Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients","volume":"96","author":"Salven","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2018.11.012_bib27","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.leu.2401121","article-title":"Mantle cell lymphoma: a retrospective study of 121 cases","volume":"12","author":"Samaha","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2018.11.012_bib28","first-page":"25","article-title":"Ras-mediated up-regulation of survivin expression in cytokine-dependent murine Pro-B lymphocytic","volume":"216","author":"Shinjyo","year":"2008","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2018.11.012_bib29","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0753-3322(97)86004-0","article-title":"Treatment of Burkitt's lymphoma in HIV-positive patients","volume":"50","author":"Straus","year":"1996","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2018.11.012_bib30","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.1998.16.11.3601","volume":"16","author":"Straus","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2018.11.012_bib31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4161\/mabs.2.2.11360","article-title":"The VEGF family in cancer and antibody-based strategies for their inhibition","volume":"2","author":"Sullivan","year":"2010","journal-title":"mAbs-Austin"},{"key":"10.1016\/j.ejphar.2018.11.012_bib32","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1349-7006.2011.01939.x","article-title":"YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo","volume":"102","author":"Tian","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejphar.2018.11.012_bib33","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bcp.2011.12.007","article-title":"Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells","volume":"83","author":"Tong","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.11.012_bib34","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1200\/JCO.2005.55.017","article-title":"Current treatment approaches for mantle-cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J. Clin. Oncol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918306666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918306666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:05:53Z","timestamp":1762142753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299918306666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":34,"alternative-id":["S0014299918306666"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.11.012","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}